20/20 Biolabs, Inc.
AIDX
$0.52
$0.000.64%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 36.54% | -36.19% | 0.41% | 15.79% | 25.14% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 36.54% | -36.19% | 0.41% | 15.79% | 25.14% |
| Cost of Revenue | 14.52% | -25.13% | 9.33% | -19.00% | 9.00% |
| Gross Profit | 86.59% | -62.06% | -20.00% | 502.07% | 88.57% |
| SG&A Expenses | 58.48% | 68.87% | -5.03% | -49.66% | -25.29% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 43.03% | 35.50% | -18.48% | -45.89% | -18.35% |
| Operating Income | -47.12% | -86.92% | 26.62% | 57.67% | 33.06% |
| Income Before Tax | -79.13% | -184.44% | -4.71% | 55.94% | 30.76% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -79.13% | -184.44% | -4.71% | 55.94% | 30.76% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -79.13% | -184.44% | -4.71% | 55.94% | 30.76% |
| EBIT | -47.12% | -86.92% | 26.62% | 57.67% | 33.06% |
| EBITDA | -48.48% | -90.38% | 26.31% | 58.01% | 32.84% |
| EPS Basic | -46.27% | -74.70% | 2.36% | 56.64% | 31.39% |
| Normalized Basic EPS | 20.00% | -79.11% | 1.06% | 56.67% | 31.40% |
| EPS Diluted | -49.08% | -74.70% | 1.89% | 56.90% | 31.39% |
| Normalized Diluted EPS | 20.00% | -79.11% | 1.06% | 56.67% | 31.40% |
| Average Basic Shares Outstanding | 123.73% | 58.76% | 7.22% | 1.65% | 0.95% |
| Average Diluted Shares Outstanding | 123.73% | 58.76% | 7.22% | 1.65% | 0.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |